Hyderabad-based pharmaceutical company Dr Reddy's Laboratories Ltd has announced that the company has got final approval from the US Food & Drug Administration (USFDA) to make and sell Cetirizine Hydrochloride syrup, 5 mg/5 ml.

Cetirizine Hydrochloride Syrup is prescribed to relieve symptoms linked with seasonal allergic rhinitis because of allergens, which consists of ragweed, grass and tree pollens in grown-ups and kids 2 years of age and older.

Symptoms treated successfully comprises sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes.

Cetirizine Hydrochloride Syrup is also indicated to relieve uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.

Dr Reddy's Laboratories, on April 28, has made announcement about the availability of Nexret, a drug for treatment of acne, in the Indian market.

In India, the anti-acne market is estimated to be about Rs 1.30 billion and is increasing at the rate of about 14% annually.

Moreover, the company, on April 22, announced that it has got final approval from the United States Food and Drug Administration (USFDA) to market Omeprazole Capsule in the strength of 40 mg.

Shares of the company, (on April 29) closed the week at Rs 544.35, down 0.6%, on the Bombay Stock Exchange (BSE). The total volume of shares traded was 17,492 at the BSE. Current EPS & P/E ratio stood at 24.68 & 22.06 respectively. The share price has touched a 52-week high of Rs 730 and a 52-week low of Rs 357.